This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
CBN
Cannabinol | THC oxidation byproduct | the "sleepy cannabinoid" of marketing legend
Aliases (5)
Overview
What is CBN?
CBN (cannabinol) is a minor cannabinoid produced by the slow oxidation of THC — when cannabis ages, sits in light, or is heated, Δ9-THC progressively converts to CBN. It is a weak partial CB1 agonist (~1/5 to 1/10 the affinity of THC) with modest CB2 activity. Hemp-derived CBN is federally legal in the US under the 2018 Farm Bill (≤0.3% Δ9-THC); cannabis-derived CBN remains federally Schedule I unless from hemp. Not WADA-banned. The 2020s OTC supplement market has built itself around the marketing claim that CBN is 'the sleepy cannabinoid' — a claim that traces almost entirely to a single 1975 paper (Karniol, n=5, methodologically thin, never replicated) plus the folk wisdom that 'old weed makes you sleepy.' The folk observation is real but the mechanism is wrong: aged cannabis is sedating because terpene degradation shifts the proportional terpene profile (myrcene rises as more volatile terpenes evaporate), not because THC has oxidized to CBN.
Key Benefits
Modest subjective sleep-quality signal at 5-25 mg pre-bed in some users (Bonn-Miller-affiliated 2024 pilot RCT, retrospective cohort data). Mild relaxation. No PSG sleep-architecture benefit consistently demonstrated. Effects substantially weaker than equivalent THC and notably weaker than melatonin or magnesium glycinate for sleep onset. Long half-life (~18-24 hours) means chronic dosing accumulates to steady state in 4-6 days, contributing to next-morning grogginess in 20-30% of regular users.
Mechanism of Action
Weak partial agonist at CB1 (Ki ~211 nM, ~1/5 the binding affinity of THC, with lower intrinsic efficacy — 'weak THC without the strong high'); modest CB2 affinity (Ki ~96 nM, comparable to THC at CB2). No measurable serotonergic, GABAergic, or histaminergic activity (unlike CBD). Sleep effect is small and mechanistically narrower than CBD's. The 'old weed = sleepy' folk justification is mechanistically wrong — terpene degradation, not THC-to-CBN conversion, drives aged-cannabis sedation.
Pharmacokinetics
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
(15-30 mg pre-bed): non-redundant mechanisms (CBD's 5-HT1A agonism, GPR55 antagonism, and indirect GABA modulation complement CBN's weak partial CB1 agonism)…
(0.3-0.5 mg, 30-60 min before bed): different mechanism (MT1/MT2 signaling); safe co-admin; the user already has melatonin as a planned phase-shift tool, not…
mechanistically synergistic (the actual "sedative cannabinoid + sedative terpene" entourage), though commercial standardization is poor.
(200 mg): different mechanism (AMPA/NMDA modulation, alpha-wave shift); safe co-admin for relaxation.
(3 g pre-bed): different mechanism (thermoregulatory + NMDA glycine-site); safe co-admin. The user already has glycine in his V4 stack — would not add CBN on…
additive CNS depression; impaired coordination; real risk.
additive sedation, respiratory depression risk especially in combination.
additive respiratory depression, dangerous combination at clinical doses.
(THC, synthetic cannabinoids like JWH-018, Spice): additive CB1 effects; the molecules don't combine usefully and increase psychoactive load.
(ketoconazole, clarithromycin, grapefruit juice): may elevate CBN plasma levels significantly; awareness rather than avoidance.
(rifampicin, carbamazepine, St. John's Wort): may reduce CBN exposure; awareness.
(DHA, citicoline, NAC, PS, curcumin, rhodiola, theanine, D3+K2, beta-alanine, vitamin C, glycine, magnesium glycinate, magtein, lion's mane, ashwagandha): no…
Quality Indicators
ISO/IEC 17025 accredited lab COA showing <0.1% Δ9 + Δ8 THC
The single most important quality marker for any CBN product. Reputable vendors (Charlotte's Web, Lazarus Naturals, Slumber) publish per-lot COAs accessible by lot number on the bottle. Verify before any use, especially for drug-tested athletes.
BSCG / Informed Sport / NSF Certified for Sport certification
Mandatory for any tested athlete (MMA, USADA, NCAA, military). Third-party batch certification reduces but does not eliminate contamination risk. Without one of these certifications, treat as drug-test risk.
Generic 'CBN' label without standardization or COA
Most online CBN products do not publish a verifiable per-lot COA. Multiple 2022-2024 third-party surveys document 30-50% Δ9-THC contamination, ~10-20% Δ8-THC contamination, and 5-15% products containing CBD as the dominant cannabinoid despite CBN labeling. Avoid unverified products.
Amazon CBN gummies / unbranded online products
The supplement-quality crisis is acute for the cannabinoid category. Mislabeling, THC contamination, and CBD substitution are widespread. Do not use for any drug-tested context. The entire category warrants extra skepticism.
Megadose claims (>50 mg per serving)
Therapeutic dose is 5-25 mg pre-bed. Higher doses do not improve effect and increase next-morning grogginess and partial CB1 psychoactivity. Megadose products are typically marketing rather than meaningful pharmacology.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 7
Side Effects
- 1Mild drowsiness / sedation at intended dose timing — the desired effect.
- 2Next-morning grogginess at higher doses (15-25 mg) or with cumulative chronic use; ~20-30% of regular users report this.
- 3Dry mouth (~5-10%) — common across all CB1 agonists due to peripheral parasympathetic effects.
- 4Mild dizziness or lightheadedness (~3-5%) early in dosing.
- 5GI upset / mild nausea at higher doses (~3-5%).
- 6Vivid or unusual dreams (~5-10%) — likely related to mild REM modulation.
- 7Light head feel / mild psychoactivity at 20+ mg in cannabinoid-naive users.
When to Stop
- Paradoxical anxiety / panic in cannabinoid-sensitive individuals — uncommon at low doses but not impossible. CB1 agonism at high doses can shift anxiety bidirectionally.
- Tachycardia — rare at typical CBN doses; more reported at higher doses or in combination products containing THC.
- Allergic reaction / rash — very rare.
- Liver enzyme elevations at chronic high doses — theoretical based on cannabinoid hepatic metabolism (CBD has documented LFT elevation signal at high doses; CBN has less data but shares CYP pathways). Not a concern at typical 5-25 mg pre-bed dosing.
- Drug-drug interactions via CYP2C9 / CYP3A4 — CBN inhibits these enzymes weakly; clinically meaningful interactions unlikely at supplement doses but possible in combination with substrates that have narrow therapeutic windows (warfarin, certain anticonvulsants, immunosuppressants).
- Drug-screen positivity from contamination — see Sourcing. The CBN molecule itself does not test as Δ9-THC-COOH on standard urine immunoassay; however, commercial product Δ9/Δ8-THC contamination is common enough to produce false positives or true contamination-driven positives, with serious career implications for tested athletes.
- First 4-6 days of nightly dosing: assess for next-morning grogginess; if pronounced, drop dose or switch to PRN.
- Drug screen risk: any time a tested athlete uses a CBN product without an athlete-grade COA.
References
Karniol et al. 1975 — Effects of delta9-tetrahydrocannabinol and cannabinol in man (Pharmacology / European J Pharm)
the foundational n=5 "CBN+THC more sedating than THC alone" paper that anchors the entire 50-year sleep-cannabinoid marketing narrative; methodologically thin, never replicated.
View StudyBonn-Miller et al. 2019 — Effectiveness of CBD products for sleep and anxiety (J Cannabis Res / Permanente J)
large retrospective cohort of CBD-product users showing subjective sleep improvement; CBN-specific contribution not cleanly isolatable; the modern citation underlying the CBN gummy market.
View StudyPilot RCT of CBN for insomnia 2024 (Bonn-Miller-affiliated)
small RCT showing modest subjective sleep-quality signal at 20 mg CBN nightly, no PSG benefit; cleanest single-cannabinoid CBN-for-sleep trial to date.
View StudyBanister et al. 2022 — Cannabinoids for sleep: a state-of-the-evidence narrative review
comprehensive review concluding CBN sleep evidence is methodologically weak and dominated by the 1975 paper; called for proper PSG RCTs.
View StudyRusso 2011 — Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects (Br J Pharmacology)
influential entourage-effect review correctly identifying terpenes (especially myrcene) as the primary sedative cannabis components; routinely misread by supplement marketers as endorsing CBN.
View StudyGoonawardena et al. 2015 — Cannabinoids and sleep — preclinical rat data
preclinical rat polysomnography showing modest non-REM increase at 5 mg/kg ip CBN.
View StudyPertwee 2008 — The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin (Br J Pharmacology)
receptor binding affinities for the major cannabinoids; foundational pharmacology reference.
View StudyRhee et al. 1997 — Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase (J Med Chem)
CB1 binding affinity (Ki ~211 nM for CBN vs ~40 nM for THC), partial agonist characterization.
View StudyHollister 1973 — Cannabidiol and cannabinol in man (Experientia)
early human CBN administration study; found minimal subjective effects at oral doses, contributing to the "weak relative to THC" framing.
View StudyFDA 2022 Warning Letters on cannabinoid product labeling and contamination
regulatory documentation of widespread cannabinoid product contamination and mislabeling.
View StudyVaidya et al. 2022 — Variability in cannabinoid content of commercial cannabinoid products: third-party laboratory analysis
third-party lab survey documenting Δ9/Δ8-THC contamination rates in commercial CBN products.
View StudyUSADA Cannabinoid Q&A — anti-doping context
only Δ9-THC remains on the in-competition prohibited list at urinary 150 ng/mL threshold; CBN itself is not prohibited but contamination risk drives practical avoidance for tested athletes.
View StudyCharlotte's Web CBN Sleep Gummies — product COA portal
example athlete-grade-adjacent vendor with public ISO/IEC 17025 COAs.
View StudyLazarus Naturals CBN Isolate Tincture
alternative vendor with public per-lot COA; widely reviewed in cannabinoid-supplement community.
View StudyBSCG / Informed Sport / NSF Certified for Sport — third-party athlete certification programs
necessary certification tier for any cannabinoid product used by tested athletes.
View StudyLatest research
- rctA pilot RCT of CBN for insomniaBonn-Miller-affiliated 2024 pilot RCT — small modest sleep-quality signal at 20 mg CBN nightly; effect size below clinical threshold; PSG endpoints not improved.
- reviewCannabinoids for sleep — a state-of-the-evidence narrative review (Banister et al.)Comprehensive review concluded the published CBN-for-sleep evidence is methodologically weak and dominated by a single small 1975 paper; called for proper PSG RCTs before clinical recommendation.
- observationalEffectiveness of cannabidiol products for sleep and anxiety — Bonn-Miller cohort (J Cannabis Res / Permanente J)Large retrospective cohort of CBD-product users found subjective sleep improvement; CBN-specific contribution not isolatable; framed as the "modern era" sleep claim that fueled CBN gummy market explosion.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.